Brokerages Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $7.50

Shattuck Labs, Inc. (NASDAQ:STTK) has received an average rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $7.50.

STTK has been the topic of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a research note on Thursday, March 27th. HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Finally, Leerink Partners initiated coverage on Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 target price on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. raised its stake in shares of Shattuck Labs by 61.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock valued at $5,657,000 after buying an additional 1,775,000 shares during the last quarter. 683 Capital Management LLC acquired a new position in Shattuck Labs in the fourth quarter valued at approximately $1,270,000. Prosight Management LP boosted its position in Shattuck Labs by 15.1% in the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock worth $8,033,000 after purchasing an additional 873,409 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. acquired a new stake in shares of Shattuck Labs during the 4th quarter worth approximately $624,000. Finally, Bank of America Corp DE increased its holdings in shares of Shattuck Labs by 135.0% during the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock valued at $226,000 after purchasing an additional 107,491 shares in the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Stock Performance

STTK stock opened at $0.82 on Friday. The firm has a market cap of $39.26 million, a price-to-earnings ratio of -0.54 and a beta of 1.76. The firm has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.22. Shattuck Labs has a one year low of $0.69 and a one year high of $11.76.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. As a group, equities analysts predict that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.